The weight loss achieved varies by specific medication and dose: semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss, tirzepatide (Zepbound) up to 15-22%, and liraglutide 3 mg (Saxenda) about 5-8%
With existing indications in type 2 diabetes and heart failure, empagliflozin could help manage the risks of cardio-renal-metabolic conditions, which are often interconnected
Secondarily, semaglutides activate neurons in key appetite-modulating relay stations (e.g
Key takeaways: Mounjaro is a dual GLP-1 / GIP receptor agonist
GLP-1 cn tc ng n cn nng thng qua hai c ch chnh: nh hng n cc trung tm i trong no (c th l vng di i), lm gim cm gic i hay thm n
Patient Experience For many people, comfort and friendliness matter just as much as medical supervision